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Clinical Review: Electrophysiology and Ablation  
AF is the most common cardiac arrhythmia of clinical significance 
with an estimated prevalence of >33 million individuals globally.1 AF 
can be associated with significant symptoms and impaired quality of 
life of affected patients while also increasing the risk of stroke, heart 
failure and death.2 AF frequently co-exists with heart failure (HF). Up to 
half of patients with HF in the Framingham Heart Study developed AF, 
while HF occurred in more than one-third of individuals with AF.3 Initial 
studies of rhythm control versus rate control to treat AF demonstrated 
equivalent outcomes, but rhythm control was pursued with electrical 
cardioversion or anti-arrhythmic medications associated with limited 
efficacy and adverse effects.4,5 Safety concerns have also been raised 
with anti-arrhythmic drugs with some medications independently 
associated with higher mortality rates.6,7
Catheter ablation has emerged as an effective treatment strategy 
in patients with AF and HF with observational studies, randomised 
controlled trials (RCTs) and meta-analyses all demonstrating clinical 
improvements compared with rate-control strategies.8–12 However, 
there remain unanswered questions as to which group of patients with 
HF might benefit the most from catheter ablation, the optimal ablation 
strategy in this population and when to pursue ablation. In this state-
of-the-art review, we assess the evidence from RCTs published within 
the last 10 years as well as additional observational and mechanistic 
studies to clarify what remains unknown and what could be a priority 
for future investigation.
Current Guidelines for Management
In patients who have co-existing AF and HF, the main aims of treatment 
are to prevent adverse outcomes, improve symptoms and maintain a 
good quality of life. The 2016 European Society of Cardiology guidelines 
on the management of AF state that the ‘indications for catheter 
ablation in HF patients with reduced ejection fraction (HFrEF) should 
be carefully balanced and procedures performed in experienced 
centres.’13 The guidelines also recognise that AF ablation can be more 
demanding in this patient cohort compared with patients without 
HF. In patients presenting acutely with AF and HF, the guidelines 
recommend focusing on normalising fluid balance, aiming for an initial 
heart rate target of <110 bpm, use of anticoagulation, inhibition of 
the renin–angiotensin–aldosterone system and early consideration 
of rhythm control.13 
However, there is no clear consensus on which patients with HF 
should be offered catheter ablation or the optimal ablation strategy 
in this setting. A growing number of studies have now been published 
to assess the effectiveness of catheter ablation on improving clinical 
outcomes in patients with AF and HF (Table 1). These studies have 
challenged previous treatment paradigms in which rate control was 
considered equivalent to rhythm control in this patient population. 
Clinical Trials of Catheter Ablation in Patients 
with AF and Heart Failure
Early trials of catheter ablation versus rate control therapy for patients 
with AF and HF included small numbers of patients and were not 
adequately powered to assess hard endpoints such as mortality. In 
the Pulmonary Vein Antrum Isolation versus AV node Ablation with 
Bi-Ventricular Pacing for Treatment of Atrial Fibrillation in patients 
with Congestive Heart Failure (PABA-CHF) study, 81 patients with 
drug-resistant AF and an EF <40  % were randomised to undergo 
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either AF ablation with pulmonary vein isolation (PVI) or AV node 
ablation with biventricular pacing.14 Additional linear lesions as well 
as targeting of complex fractionated electrograms (CFE) were allowed 
according to the preference of the centre and operator. Patients who 
underwent PVI showed improvements in the composite primary 
endpoint including EF measurement with echocardiography, 6-minute 
walk test and a quality of life score compared with AV node ablation 
with biventricular pacing. The majority of patients in both arms of the 
study had ischaemic cardiomyopathy (73  % and 68  %, respectively) 
and a mean duration of AF of 4 years. In the ablation group, 51 % had 
persistent or long-standing persistent AF where clinical outcomes 
are known to be inferior to paroxysmal AF. Intriguingly, those patients 
who underwent AV node ablation and biventricular pacing did not 
demonstrate more significant improvements in their LVF (EF 28  %), 
although this group of patients appeared to have narrow QRS intervals 
at baseline (90 ± 10 ms).14 
In a smaller study (41 patients), MacDonald et al. found no difference in 
EF measured using cardiac MRI in patients undergoing catheter ablation 
versus medical rate control at 6-month follow-up.15 In this study, only 
patients with persistent AF were included, while mean LVEF measured at 
baseline was only 16.1 % in the ablation group and 19.6 % in the medical 
group, suggesting more advanced disease. Around 90 % of patients were 
in New York Heart Association (NYHA) class III or above. Furthermore, 
only 50 % of patients in the ablation group maintained sinus rhythm at 
the end of the study. Although the study was likely underpowered to 
detect a difference in the primary endpoint, it does raise the importance 
of careful consideration of the likelihood of success in specific groups 
of patients with AF and HF.15 In a subsequent study (ARC-HF), with 
an improvement in maintenance of sinus rhythm and higher single-
procedure success rate, catheter ablation led to an increase in peak 
oxygen consumption compared with rate control.16 The Catheter Ablation 
Versus Medical Treatment of Atrial Fibrillation (CAMTAF) trial included a 
higher proportion of patients with non-ischaemic cardiomyopathy 
(74 %) compared to previous trials, while 92 % of all patients in the study 
had long-standing persistent AF.17 In addition, those patients who were 
thought to be clearly symptomatic from AF were excluded, as the aim 
of the study was to use ablation to treat HF rather than symptomatic 
refractory AF. An improvement in LVEF, peak oxygen consumption and 
quality of life score was seen in the ablation arm versus medical rate 
control. Interestingly, the duration of continuous AF was significantly 
lower in the CAMTAF study compared with that in the study by 
MacDonald et al.13 (24 months versus 53 months).17 
In these early RCTs, the duration of follow-up ranged 6–10 months. 
Meanwhile, the single-procedure success rates of catheter ablation 
ranged 38–71 %, with overall success rates ranging 50–88 %. Whether 
catheter ablation maintained sinus rhythm in the long term is 
unclear based on these early results. The ablation strategy was 
also heterogeneous with all patients undergoing at least PVI, but 
a large proportion had additional linear lesions dependant on the 
operator and centre. A meta-analysis of these trials revealed that an 
improvement in LVEF was the most consistent benefit in functional 
outcome with a mean difference of 8.53  % (95  % CI [6.40–10.67]).11 
This raises the issue of whether catheter ablation would improve 
functional outcome in patients with HF and preserved EF (HFpEF) 
with limited data that suggest that these patients may be older, 
have more co-morbidities, be more commonly female and may have 
higher procedural complications.18,19 However, a recent study of 230 
patients found no differences in arrhythmia-free recurrence, NYHA 
functional class and procedural characteristics between HFpEF and 
HFrEF patients undergoing AF ablation.20 This was a single-centre, 
retrospective study and further research is needed to assess the role 
of catheter ablation in HFpEF. 
The early RCTs included small numbers of patients and were therefore 
adequately powered only to assess surrogate end-points such as 
ejection fraction, exercise capacity and quality of life. More recently a 
number of highly anticipated trials have now been published assessing 
hard end-points such as mortality. In the Ablation vs. Amiodarone for 
Treatment of Atrial Fibrillation in Patients with Congestive Heart Failure 
and an Implanted ICD/CRTD (AATAC) study, patients with persistent 
AF, LVEF <40 % and NYHA Class II–III heart failure were randomised to 
either receive catheter ablation or amiodarone.10 Unlike previous RCTs, 
the aim in both arms was rhythm control with a primary endpoint of 
AF recurrence and secondary endpoints including all-cause mortality 
and unplanned hospitalisation. Interestingly, catheter ablation was 
superior to amiodarone in achieving freedom from AF recurrence as well 
reducing all-cause mortality and unplanned hospitalisation rates. During 
a longer 24-month follow-up period, 70 % of patients in the ablation arm 
(95 % CI [60–78]) and 34 % in the control arm (95 % CI [25–44]) remained 
arrhythmia-free. The duration of AF at randomisation was significantly 
shorter than in previous studies (8.6 months in the ablation arm and 
8.4 months in the amiodarone arm), while all patients had an implanted 
device, which strengthened the quality of the outcome data. A lower 
all-cause mortality rate (secondary endpoint) was also reported in the 
catheter ablation arm (8 % versus 18 %; p=0.037). 
Although promising, it should be noted that the AATAC study compared 
ablation with a drug known to have significant toxicities; 10.4  % of 
treatment failures in the amiodarone group had the drug withdrawn 
due to adverse effects. The study does, however, raise the importance 
of early treatment before long-standing persistent AF develops.10
In this context, the Catheter Ablation versus Standard Conventional 
Therapy in Patients with Left Ventricular Dysfunction and Atrial 
Fibrillation (CASTLE-AF) trial assessed the impact of ablation on 
mortality and HF progression rates.21 In this study, 363 patients with 
symptomatic paroxysmal or persistent AF, NYHA II–IV heart failure, LVEF 
<35  % and an implanted device were randomised to receive either 
catheter ablation or medical therapy (with rhythm control encouraged). 
Over a median follow-up of 37.8 months, the primary composite 
endpoint of death from any cause or hospitalisation due to HF was 
significantly less frequent in the ablation group than the medical 
therapy group (HR 0.62; 95 % CI [0.43–0.87]). Similar to the AATAC trial, 
all patients had AF recurrence monitored with an implanted device. 
A mortality benefit (13.4 % versus 25 %; HR 0.53; 95 % CI [0.32–0.86]; 
p=0.01) was also demonstrated in the ablation arm, which was driven 
by a lower rate of cardiovascular death.21 
CASTLE-AF builds on the accumulating evidence that catheter ablation 
may have benefits in patients with HF but does not necessarily add 
clarity as to which patients with HF should be targeted for ablation. 
The patients appeared to be highly selected with >3000 screened for 
eligibility, but only 13.2 % ultimately enrolled. Patients whose implanted 
device was from a different vendor (study sponsored by Biotronik) 
were excluded (32.4  %). Among the ablation arm, 69  % had NYHA 
class I or II HF, 40  % had ischaemic cardiomyopathy and 30  % had 
paroxysmal AF. Long-standing persistent AF was observed in 28 % of 
patients in the ablation arm and 30 % in the medical therapy arm. This 
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clearly reveals a highly heterogeneous cohort of patients with HF. There 
was also significant heterogeneity in terms of the catheter ablation 
procedure itself with the aim of the procedure to isolate all pulmonary 
veins and achieve sinus rhythm. Additional lesions involving the cavo-
tricuspid isthmus, roof, superior vena cava and inferior vena cava were 
permitted at the discretion of the operator. 
Although promising, the results of CASTLE-AF may not apply to 
asymptomatic patients with HF, older patients (with a median age 
of 64 years in the study) as well as patients with advanced HF. 
Indeed, there is some evidence to suggest that some groups of 
patients with HF respond much better to catheter ablation. In the 
Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation 
and Systolic Dysfunction (CAMERA-MRI) study, patients with idiopathic 
cardiomyopathy and persistent AF were randomised to undergo either 
catheter ablation or medical rate control.22 All patients had a cardiac 
MRI scan at baseline after optimisation of rate control to assess LVEF 
and presence of late gadolinium enhancement (LGE) – a surrogate of 
ventricular fibrosis. These patients were younger (mean age 59 ± 11 
years in ablation arm and 62 ± 9.4 years in the medical therapy arm) 
and had a mean LVEF of 35  %, but a large majority (72–76  %) had 
long-standing persistent AF. The primary outcome was a change in 
LVEF during a repeat MRI at 6 months. The ablation group had a better 
improvement in LVEF compared with medical rate control, but, more 
interestingly, among patients undergoing catheter ablation, those who 
were LGE negative at baseline had an even better response compared 
with those who had evidence of LGE on MRI. These findings indicate 
that restoration of sinus rhythm in a cohort of patients with no other 
apparent cause of their cardiomyopathy may result in improved LV 
function, but a pure effect of improved heart rate cannot be excluded 
for the effect seen. 
The true value of CAMERA-MRI may be that risk stratification tools 
such as cardiac MRI with LGE could identify a cohort of patients who 
may be super-responders to catheter ablation.22 These findings are 
consistent with a previous report by the same authors in which 15/16 
LGE-negative patients with long-standing persistent AF who underwent 
catheter ablation maintained sinus rhythm at 6 months with a 
significant improvement in LV function.23 However, it remains unclear 
if ablation improves outcomes beyond LV function in the CAMERA-MRI 
study as there were no data on HF-related hospitalisations or mortality 
in this cohort. 
Complication rates related to the catheter ablation procedure may 
also be higher in patients with HF compared with general cohorts 
of patients undergoing an AF ablation, which bears consideration 
during patient selection. In the CASTLE-AF study, procedure-related 
complications or serious adverse events occurred in 7.8 %, while in a 
contemporary cohort of general patients undergoing AF ablation the 
complication rate was 2.3 %.24 
Differences in Electrophysiological Substrate 
Within Patients with Heart Failure and Between 
Patients With and Without Heart Failure: 
Implications for Ablation Strategy
Persistent AF appears to be more prevalent than paroxysmal AF in 
patients with HFrEF.25 There is building momentum towards increasing 
the single-procedure success rates for paroxysmal AF with more 
reproducible, standardised PVI workflows, incorporating composite 
ablation indices such as ‘ablation index’ or tracking inter-lesion 
distance to minimise gaps between adjacent lesions.26,27 However, 
standardised approaches for catheter ablation of persistent AF remain 
a long way off, with the results of the Substrate and Trigger Ablation for 
Reduction of Atrial Fibrillation Trial Part II (STAR AF II) demonstrating no 
benefit of additional linear ablation or ablation of complex fractionated 
activity (CFE) to PVI alone in this population.28 This is particularly 
relevant in patients with HF as the results from an international 
multicentre registry have suggested that long-term success rates 
for persistent AF ablation are significantly lower in patients with HF 
compared with those without HF (57.3 % versus 75.8 %; p<0.001), while 
there was no significant difference in success rates for paroxysmal AF 
ablation (78.7 % versus 85.7 %; p=0.186).29 
Most of the clinical trials of AF ablation in HF described above have 
had significant heterogeneity between studies in terms of the ablation 
protocol used, while data comparing different ablation strategies in 
HF populations are sparse. In a meta-regression analysis of clinical 
trials and observational studies of AF ablation in HF patients, there 
was no difference in sinus rhythm maintenance between a PVI 
approach versus extensive left atrial ablation (linear lesions or CFE 
ablation).30 However, there are some cardiomyopathies with extensive 
left atrial structural remodelling such as hypertrophic cardiomyopathy 
or cardiomyopathies secondary to valvular heart disease.12 A higher 
prevalence of CFE has also been reported in some groups of patients 
with HF.12 Only a minority of these patients with significant structural 
and electrical remodelling have undergone PVI alone in observational 
studies.12 Whether PVI alone is adequate or sufficient or whether more 
aggressive substrate modification strategies are required in these 
groups of patients remains unclear.
Even in patients with paroxysmal AF, those patients with HFrEF 
appear to have more non-PV triggers than patients with normal LVEF. 
Furthermore, in a cohort with HFrEF, when ablation of non-PV triggers 
was performed in addition to PVI, a significantly improved long-term 
ablation success was achieved compared with PVI alone (75.0  % 
versus 32.2 %; p<0.001).31 
There are important structural and anatomical abnormalities in the 
atria of patients with HF compared with patients without HF that may 
impact on their electrophysiological properties. Using a cohort of 
patients with symptomatic HF and age-matched controls, Sanders et al. 
demonstrated that patients with HF had an increase in atrial effective 
refractory period, no change in the heterogeneity of refractoriness and 
an increase in atrial conduction time along the low lateral right atrium 
and coronary sinus.32 They also found evidence of functional delay 
at the crista terminalis and indirect evidence of conduction slowing 
across the left atrium and Bachmann’s bundle.32 Taken together, these 
electrophysiological differences may have led to the observation of 
increased inducibility and duration of AF in patients with HF.32 Specific 
causes of cardiomyopathy such as valvular heart disease, which 
may cause advanced structural remodelling in the left atrium, also 
demonstrate different conduction patterns. Patients with persistent AF 
associated with mitral regurgitation (MR) had greater conduction delay 
and anisotropy in the posterior left atrium associated with fractionated 
electrograms in these regions compared with patients with MR but 
without AF.33 
The ideal AF ablation protocol in patients with HF remains unclear. 
Although PVI alone may be appropriate in certain groups of patients, 
further investigation and innovation in ablation tools are required to 
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clarify the role of additional linear lesions and develop reproducible 
strategies in patients with HF and persistent AF. In cohorts of high-risk 
patients with advanced structural remodelling, extensive left atrial 
ablation may be needed first-line, but an individualised strategy with a 
greater understanding of the underlying electrophysiological substrate 
will likely be required. 
Interestingly, in a recent study, Halder et al. used CFEs as a surrogate 
marker of substrate complexity.34 In patients without HF who had 
persistent AF, a higher baseline burden of CFEs was seen in both 
the left and right atrium compared with patients with AF and HF. This 
finding challenges the belief that the presence of structural heart 
disease leads to additional complexity in atrial substrate. However, the 
importance of distinguishing between which is the initiating disease 
may be relevant to explain these findings – whether AF occurred first 
leading to subsequent development of HF or whether HF occurred first. 
Halder et al. suggest that those patients without HF with persistent AF 
may have a more complex primary bi-atrial substrate as a result of the 
primary electrical disturbance.34 In their study, a left atrial step-wise 
ablation strategy with more extensive substrate modification resulted 
in a higher single-procedure arrhythmia-free survival rate at 12 months 
in the HF group compared with the non-HF group.34 Taken one step 
further, whether identification of patients who develop AF first prior 
to HF development may be a means of stratifying which patients may 
respond to rhythm control with ablation remains unclear and warrants 
further investigation. In reality, this is difficult to perform in clinical 
practice due to the large numbers of patients presenting with both AF 
and HF with no clear indication of which was the primary disturbance. 
Risk Stratification Tools for Atrial  
Fibrillation Ablation
Improved risk stratification tools to identify patients with AF and HF 
who might respond best to catheter ablation will be of great value to 
electrophysiologists to reduce unnecessary procedures in patients 
unlikely to benefit or to offer more procedures to patients most likely 
to see clinical benefit. A number of clinical parameters have been 
associated with clinical outcome following AF ablation including 
type of AF, age, gender, LVEF, left atrial size/volume, and presence of 
hypertension, obstructive sleep apnoea or diabetes.35 
The use of cardiac MRI to assess left atrial (LA) structure and function 
has also led to the identification of additional parameters such as 
LA reservoir function,35 LA sphericity36 and LA fibrosis37 that may 
be related to ablation outcome. The extent of baseline atrial LGE 
(as a surrogate of fibrosis) (Figure 1), in particular, has received 
significant attention, with some centres reporting limited value in risk 
stratification,38 but a growing volume of literature supporting the belief 
that patients with a higher burden of atrial LGE have worse outcomes 
following AF ablation.39,40 
Improved risk stratification tools to identify subsets of patients with 
HF who might respond better to catheter ablation are warranted and 
may also help to tailor ablation strategies. Based on the results of the 
CAMERA-MRI study, cardiac imaging, in particular, bears consideration 
in selecting the right patients for catheter ablation. The ongoing 
Delayed Enhancement MRI-guided Ablation Versus Conventional 
Catheter Ablation of Atrial Fibrillation (DECAAF-II) trial (NCT20529319) 
will examine the impact of targeting LGE-MRI detected atrial fibrosis 
during AF ablation to improve procedural outcomes. Although this 
study will include a general cohort of patients, it is likely that it will also 
include a subset with co-existing HF. 
Non-invasive electrocardiographic imaging, whereby a subject 
undergoes a multi-detector CT scan while wearing a 252-electrode vest 
on the thorax to record epicardial unipolar electrograms to reconstruct 
epicardial electrical potentials on patient-specific geometry, also 
offers potential as a tool to guide ablation strategy.41 In patients 
with persistent AF, electrocardiographic imaging has been used to 
demonstrate the increasing complexity of AF drivers with prolonged AF 
duration.42 Prior knowledge of the principle locations of AF drivers may 
help guide ablation strategy in specific groups of patients.43 
Based on results of completed clinical trials of AF ablation in HF (Table 1), 
patients who tend to have the least benefit from catheter ablation 
appear to have a higher NYHA functional class, longer duration of AF 
and extensive structural remodelling. Those who appear to respond 
best to catheter ablation have no other structural abnormalities related 
to their cardiomyopathy.22 There may be a third group of patients that 
have both AF and an underlying occult cardiomyopathy that persists 
despite improvements in AF burden after ablation.44
What is clear from all the trials to date is that HF populations with 
AF are highly heterogeneous; this can have a significant impact on 
clinical outcomes. However, the presence of significant structural heart 
disease does not universally imply more complex electrophysiological 
substrate and tailored strategies will likely be required to obtain the 
best clinical outcome.34
Future Perspectives
Despite significant progress in catheter ablation in patients with HF, a 
number of unanswered questions remain including the optimal means 
of risk stratification of patients with HF to AF ablation, optimal ablation 
technique and timing of catheter ablation. Whether intervention 
will be cost effective if patients require multiple re-do ablations, 
particularly as HF progresses, is also unclear. A number of clinical 
trials are currently underway that may provide some clarification. The 
Figure 1: Atrial Late-gadolinium Enhancement on Cardiac 
MRI and Corresponding 3D Shells Demonstrating Regions 
of Scar
A and B: 3D late-gadolinium-enhanced MRI scan of the left atrium in a patient with persistent 
AF. Images obtained in an axial orientation and show regions of hyper-enhancement (white 
arrows) in two different slices. C and D: 3D shells of the left atrium in the same patient 
generated using the image intensity ratio technique. Scar is shown in red and normal 
myocardium in blue; C: postero-anterior view; D: antero-posterior view.
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AF Ablation in Patients with Heart Failure
Ablation of Atrial Fibrillation in Heart Failure Patients (CONTRA-HF) 
trial will investigate the impact of cryoablation in patients with HF 
and implanted cardiac devices/cardiac resynchronisation therapies 
(NCT03062241). An improved reproducibility of the ablation procedure 
itself is expected in the cryoablation arm and its impact on hard 
endpoints such as mortality will be welcome. The Catheter Ablation 
Versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation (CABANA) 
trial will also assess the impact of ablation on the hard endpoints 
of mortality, stroke and hospitalisations in a large cohort (>2,000) of 
patients (NCT00911508). Patients with both HFrEF and HFpEF will be 
included in the study, which will likely give further insights into the 
optimal management of patients with AF and HF. 
The Catheter Ablation Versus Medical Therapy in Congested Hearts 
with AF (CATCH-AF) trial will assess the impact of catheter ablation 
in patients with newly diagnosed symptomatic AF with the aim 
of assisting electrophysiologists in understanding the benefits of 
early AF ablation (NCT02686749). The Atrial Fibrillation Management 
in Congestive Heart Failure With Ablation (AMICA) trial will 
investigate whether PVI alone in patients with persistent AF or long-
standing persistent AF improves outcomes compared with best 
medical therapy (NCT00652522). This will allow the impact of a 
standardised procedure to be investigated in a less heterogeneous 
group of patients. 
The Randomised Ablation-based Atrial Fibrillation Rhythm Control 
Trial in Patients with Heart Failure and High Burden Atrial Fibrillation 
(RAFT-AF) will assess the cost-effectiveness of an ablation strategy in 
patients with HF as well as assess hard endpoints including all-cause 
mortality; patients with HF will be stratified according to those with 
HFrEF and HFpEF (NCT01420393). 
The advent of permanent His bundle pacing to preserve physiological 
conduction of the ventricles and enable a means of achieving 
cardiac resynchronisation therapy could also offer an alternative 
management strategy in selected groups of patients with AF and HF, 
if combined with AV node ablation.45 Further studies to assess clinical 
outcomes using this strategy are anticipated. 
Conclusions
AF ablation in certain patients with HF may be safe and effective, but 
most data in this setting are derived from experienced centres. Ablation 
may not be appropriate in patients with advanced HF, poor functional 
status or in those with extensive structural remodelling. Improved 
risk stratification tools and standardisation of ablation strategies 
in different groups of patients should lead to the development of 
patient-orientated approaches that seek to identify the patients 
most likely to benefit from catheter ablation and improve procedural 
success rates in those patients. n
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